10:51 AM EST - Aeterna Zentaris Inc. : Concluded a successful meeting of the clinical investigators for the confirmatory Phase 3 trial of Macrilen™ (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency. As a result, the Company is confident that it will complete the confirmatory trial by year-end 2016. Aeterna Zentaris Inc.
shares T.AEZ are trading up $1.07 at $4.92.
